ESTEVE is a chemical and pharmaceutical group that has focused its business on the area of health since 1929, when Dr. Antoni Esteve i Subirana founded the first company. Today ESTEVE is renowned for its devotion to research, its international expansion, its ability to generate strategic alliances and its commitment to sustainability.
Its head office is in Barcelona, it has eight subsidiaries on three continents (Europe, America and Asia) and sells its products in more than 60 countries. Through its three business activities–Pharmaceuticals, Generics, and Chemicals– it covers the whole drug life-cycle.
At ESTEVE –yet another year– true to our commitment to transparency and sustainability, we wish to share our economic, social and environmental results for 2017, as well as our goals for 2018.
In the area of
The Group’s strategic plan continues to progress globally, although overall economic performance is below forecast and our plan for 2020. The greatest deviation is due to price erosion in the North American generics market. Despite this, we have continued to make more strategic investments in industrial assets and other strategic projects.
Our focus is people’s health and well-being through the research and development of new products. In fact, our efforts have borne fruit in the form of a new entity: the E-58425 co-crystal. This product, the first of its kind, represents a major step in the treatment of pain, an area that is not receiving adequate coverage. As of the publication of this report, we are waiting to share the preliminary Phase III results with the competent health authorities.
In the internal social area, we would like to call attention to the progress on the cultural transformation project made this year and the corporate headquarters relocation scheduled for 2018. This switchover to digitalisation will serve as a lever for innovation allowing us to work better, more collaboratively and flexibly, creating more shared value.
And lastly, as part of our commitment to society and the environment, we would like to highlight our participation in innovation programmes in collaboration with start-ups to provide solutions to unresolved issues such as facilitating access to patient information leaflets for the deaf. With regard to the environmental area, we would like to underline our collaboration with a start-up promoted by Ship2B, with the aim of developing climate change risk software to anticipate actions and reduce greenhouse gas emissions.
In today's environment of disruption, complexity and growing uncertainty, we must be prepared to adapt our businesses to the constantly changing needs of our consumers, regulators, customers and investors in order to remain competitive and provide value.
Value creation and trust are key elements for all organisations. For us, transparency and compliance give us the opportunity to work every day to find improvements for health, building the future by taking care of the present.
This report has been drawn up according to the international standards of the Global Reporting Initiative (GRI) found in the latest version of the GRI Standards, and verified by an independent third party, which makes it possible for us to remain true to our commitment to transparent reporting to our stakeholders.
The Board of Directors promotes a sustainable business model, aware of the active role that companies play in achieving a sustainable environment and the well-being of humanity.
We hope you will find this latest edition of our Sustainability Report of interest.